MedPath

Assessing methylene tetrahydrofolate reductase (MTHFR) genetic polymorphisms and dietary folate intake in platinum resistant and platinum sensitive ovarian patients

Not Applicable
Completed
Conditions
Ovarian cancer
MTHFR gene polymorphisms
Cancer - Ovarian and primary peritoneal
Registration Number
ACTRN12618001138279
Lead Sponsor
Endeavour College of Natural Health
Brief Summary

The results of this trial revealed strong associations between dietary B6, B12, zinc and folate intakes in heterozygous A1298C and C677T carriers and platinum response. There is also an association between serum folate, homocysteine, dietary zinc, B12 intakes and platinum sensitivity in participants without a mutation. Further research is required to understand the direction the association flows in order to be able to provide any sound nutritional recommendations, however this study provides a foundation for future research on the role of diet on platinum response in epithelial ovarian cancer patients in relation to MTHFR polymorphisms. Furthermore, the high prevalence of MTHFR mutations in this population may require further investigation into the role of these polymorphisms in the development and/or progression of ovarian cancer. These results require studies on a larger group of participants to confirm the findings shown here.

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Female
Target Recruitment
25
Inclusion Criteria

•Diagnosed with ovarian, fallopian tube, epithelial or peritoneal cancer
•Completed first line platinum therapy
•Diagnosed with refractory/resistant disease or platinum sensitive disease a minimum of 6 months after platinum therapy

Exclusion Criteria

•Non-English speaking
•Never received a platinum drug for ovarian cancer diagnosis

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath